TECOS supports the DPP-4 inhibitor sitagliptin for T2D patients with CV disease and CKD

The recent Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)1 has provided further support for the use of the DPP-4 inhibitor sitagliptin in type 2 diabetes mellitus patients with pre-existin